Sharemaestro company-news research for Twist Bioscience Corp (TWST), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest TWST news and sentiment
Twist Bioscience Corp
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score52Neutral is 50
Early balanced news score
31/100 evidence confidence
97% direct company focus
30 current stories across 11 publishers
Current company news
Early balanced news score
30 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone54/100
→
Published 30-day score52/100
Latest source headline
Twist Bioscience Stock Gains Lilly AI Drug Discovery Partnership Exposure
simplywall.st · 21 Sep 2026 07:34
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
30 current stories are mapped specifically to TWST.
The score uses 11 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.554.
Confidence is 31/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
31/100
Confidencethin evidence
97%/100
Company news30 company stories
85/100
Story agreement15/100 difference
News history
Daily score and story count over 30 days
26 Aug10 Sep24 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence11
0.554 after freshness weightingSource breadth100
11 independent publishersCompany relevance97
share tied directly to this companyFreshness29
recency-weighted evidenceAgreement85
how closely stories agreePublisher mix79
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks19 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
18 Sep 202651USD 166.99+31.3%
11 Sep 202645USD 127.22+2.0%
04 Sep 202652USD 124.72-11.8%
28 Aug 202653USD 141.38-2.9%
21 Aug 202659USD 145.59+22.8%
14 Aug 202655USD 118.57+2.5%
07 Aug 202657USD 115.67+26.3%
31 Jul 202656USD 91.55+1.4%
Provisional evidence
News subjects
What is shaping the score
Earnings5911 stories · 37%
Market update5211 stories · 37%
Analyst action313 stories · 10%
Deals and strategy562 stories · 7%
Regulatory and legal271 stories · 3%
Guidance591 stories · 3%
Balance sheet501 stories · 3%
Source mix
Where the evidence comes from
simplywall.st575 stories · 17%
Stock Titan404 stories · 13%
Investing.com513 stories · 10%
finance.yahoo.com512 stories · 7%
Trefis502 stories · 7%
dars.gov.et251 stories · 3%
Claim Depot271 stories · 3%
Recurring subjects
Subjects appearing most often
Life Sciences10Earnings9Financial Markets6Finance6Biotech6Technology5AI3Healthcare2Drug Discovery2Antibody Discovery2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
09 Jul50 neutral23 Sep 10:59
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 23 Sep 10:59 | 52 | +0 | 30/100 (-2) | 30 (-1) | Provisional |
| 21 Sep 23:59 | 52 | +0 | 32/100 (-1) | 31 (+2) | Provisional |
| 20 Sep 23:59 | 52 | +0 | 33/100 (-2) | 29 (-2) | Provisional |
| 19 Sep 23:59 | 52 | +0 | 35/100 (0) | 31 (-19) | Provisional |
| 17 Sep 23:59 | 52 | +4 | 35/100 (+7) | 50 (+1) | Provisional |
| 16 Sep 23:59 | 48 | +1 | 28/100 (+1) | 49 (+3) | Provisional |
| 15 Sep 23:59 | 47 | +2 | 27/100 (-9) | 46 (-12) | Provisional |
| 10 Sep 23:59 | 45 | +0 | 36/100 (-1) | 58 (-1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#157Tone
simplywall.stDirect company coverageStored article
Twist Bioscience Stock Gains Lilly AI Drug Discovery Partnership Exposure
Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the company confirmed a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company (NYSE:LLY). As part of the strategic partnership, Twist will provide antibody characterization data services for TuneLab. It will also provide data to support AbLab, an antibody developability prediction model, and high-throughput wet-lab data that can help train and improve those models. Through
AIBiotechDrug DiscoveryExperimental DataPartnershipRevenue Growth
- Published
- 21 Sep 2026 07:34
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 43/100
- 30-day weight
- 11.7% of the score · 2.1d old
- Duplicates
- 2 consolidated
#2—Not directional
TrefisDirect company coverageScored from headline
Twist Bioscience Stock: 7 Straight Green Days, Up 33%
- Published
- 21 Sep 2026 05:21
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.2d old
- Duplicates
- 2 consolidated
#3—Not directional
The Chronicle-JournalDirect company coverageScored from headline
Twist Bioscience Corporation - Common Stock (NQ: TWST
- Published
- 20 Sep 2026 03:11
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.3d old
- Duplicates
- 1 consolidated
#459Tone
simplywall.stDirect company coverageScored from headline
Twist Bioscience (TWST) Stock Could Be 16% Undervalued On DNA Synthesis Market Outlook
- Published
- 19 Sep 2026 20:33
- News subject
- Guidance
- Why this score
- Positive valuation view
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 21.6% of the score · 3.6d old
- Duplicates
- 1 consolidated
#570Tone
TechStock²Direct company coverageScored from headline
Twist Bioscience Stock Jumps 11% on Lilly TuneLab Deal, but the Revenue Terms Are Missing
- Published
- 17 Sep 2026 19:20
- News subject
- Earnings
- Why this score
- Large positive market reaction, Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 57/100
- 30-day weight
- 18% of the score · 5.7d old
- Duplicates
- 1 consolidated
#660Tone
StocksToTradeDirect company coverageScored from headline
Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Momentum
- Published
- 17 Sep 2026 16:33
- News subject
- Deals and strategy
- Why this score
- Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 48/100
- 30-day weight
- 13.5% of the score · 5.8d old
- Duplicates
- 1 consolidated
#7—Not directional
finance.yahoo.comDirect company coverageStored article
Twist Bioscience (TWST) Is Up 14.0% After Lilly AI Drug Discovery Tie-Up Is Announced - Has The Bull Case Changed?
On 16 September 2026, Twist Bioscience announced an agreement with Lilly TuneLab, under which Twist will provide antibody characterization data services using preferred Twist protocols to generate high-quality wet lab data that feed Lilly's AI/ML drug discovery models. This collaboration effectively plugs Twist's DNA and antibody capabilities into Lilly's AI-driven discovery ecosystem, potentially deepening Twist's role in data-rich, AI-enhanced antibody development workflows across the biopharma industry. We'll now examine how Twist's integration into Lilly's AI-enabled TuneLab platform could
AIAntibody DiscoveryBiopharmaEarningsEquity DilutionFinancial Markets
- Published
- 17 Sep 2026 10:10
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.0d old
- Duplicates
- 1 consolidated
#8—Not directional
Investing.comDirect company coverageStored article
Twist Bioscience stock rises on Eli Lilly partnership deal
Twist Bioscience Corp (NASDAQ:TWST) shares climbed 3% following the announcement of a partnership with Eli Lilly and Company's TuneLab. Under the agreement, Twist will provide antibody characterization data services for TuneLab, aiming to accelerate biotech innovation by connecting experimental data with AI-enabled drug discovery. This collaboration will allow TuneLab users to access Twist's services with preferred protocols and pricing, contributing to more efficient antibody drug discovery.
Life SciencesTechnology
- Published
- 16 Sep 2026 18:05
- News subject
- Deals and strategy
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.7d old
- Duplicates
- 1 consolidated
#9—Not directional
FinvizDirect company coverageStored article
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Antibody characterization data generated by Twist supports TuneLab AI models designed to accelerate antibody discovery SOUTH SAN FRANCISCO, Calif., September 16, 2026--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). Twist is a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab was created to accelerate biotech innov
AI MlAntibody DiscoveryBiotech
- Published
- 16 Sep 2026 14:53
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.8d old
- Duplicates
- 1 consolidated
#10—Not directional
seekingalpha.comDirect company coverageStored article
Twist Bio, and Gingko rise after agreements with Lilly TuneLab
[Two coloured ropes knotted together] Richard Drury Twist Bioscience (TWST [https://seekingalpha.com/symbol/TWST]) and Ginkgo Bioworks (DNA [https://seekingalpha.com/symbol/DNA]) traded higher on Wednesday after announcing agreements with Lilly TuneLab, a collaborative drug discovery platform established by Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]). As part of its agreement with Lilly, Twist Bio (TWST [https://seekingalpha.com/symbol/TWST]) said that it will provide antibody characterization data services to TuneLab companies accessing AI/ML drug discovery models trained on Lilly-o
AI MlBiotechDrug Discovery
- Published
- 16 Sep 2026 14:36
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.8d old
- Duplicates
- 1 consolidated
#1157Tone
finance.yahoo.comDirect company coverageStored article
AI and Next-Gen Sequencing Strengthens Twist Bioscience Corp. (TWST)
Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains con
AIBiotechGrowth Stocks
- Published
- 16 Sep 2026 13:59
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- 1.3% of the score · 6.9d old
- Duplicates
- 1 consolidated
#1260Tone
simplywall.stDirect company coverageScored from headline
Twist Bioscience (TWST) Shares Climbed, So What Is Catching Investors' Attention?
- Published
- 15 Sep 2026 05:41
- News subject
- Market update
- Why this score
- Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 1% of the score · 8.2d old
- Duplicates
- 1 consolidated
#1340Tone
Kalkine MediaDirect company coverageStored article
Twist Bioscience HR SVP Paula Green Sells Shares to Cover RSU Tax Withholding
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp, sold 907 shares of company common stock on September 8, 2026. This transaction, valued at $122.624 per share, was not a discretionary trade but a mandatory "sell to cover" sale to meet tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs). After the sale, Green directly holds 117,014 shares of Twist Bioscience.
EarningsFinance
- Published
- 10 Sep 2026 21:26
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 40/100
- 30-day weight
- 6.3% of the score · 12.6d old
- Duplicates
- 1 consolidated
#1426Tone
Investing.comDirect company coverageStored article
BWS Financial initiates Twist Bioscience stock with sell rating
BWS Financial initiated coverage on Twist Bioscience (NASDAQ:TWST) with a sell rating and a price target of $45.00, citing its significant premium compared to competitors and overvaluation. Analyst Hamed Khorsand highlighted pricing pressure from integrated incumbents, the non-commercial nature of a recent stock-driving research evaluation, and increasing insider selling. Despite a remarkable stock performance over the past year, the company is not expected to be profitable this year.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 09 Sep 2026 14:28
- News subject
- Analyst action
- Why this score
- Analyst downgrade, Sell Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 48/100
- 30-day weight
- 2.2% of the score · 13.9d old
- Duplicates
- 1 consolidated
#15—Not directional
BioSpaceDirect company coverageStored article
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
Twist Bioscience announced that its CEO, Emily M. Leproust, Ph.D., and CFO, Adam Laponis, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference. The event is scheduled for September 15, 2026, at 1:25 pm Eastern Time in New York City and will be webcast live. A replay of the chat will be available for 30 days on the company's investor relations website.
BiotechConferenceEarningsFinancial MarketsHealthcareLife Sciences
- Published
- 09 Sep 2026 13:52
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.9d old
- Duplicates
- 1 consolidated
#16—Not directional
MT NewswiresDirect company coverageScored from headline
UBS Initiates Coverage on Twist Bioscience With Neutral Rating, $144 Price Target
- Published
- 09 Sep 2026 12:17
- News subject
- Analyst action
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.9d old
- Duplicates
- 1 consolidated
#17—Not directional
simplywall.stDirect company coverageScored from headline
Twist Bioscience (TWST) Stock Looks Undervalued On Cash Flow But Overvalued On Sales
- Published
- 09 Sep 2026 07:00
- News subject
- Balance sheet
- Why this score
- Positive valuation view, Negative valuation view
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.2d old
- Duplicates
- 1 consolidated
#1869Tone
Insider MonkeyDirect company coverageStored article
Twist Bioscience (TWST) Rallied as AI and Pharma Drive DNA Demand
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the "Artisan Mid Cap Fund". The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and geopolitical uncertainty. The portfolio generated strong absolute returns and outperformed the Russell Midcap® Growth Index, benefiting from semiconductor exposure within IT and strong stock select
BiotechConsumer DiscretionaryEarningsHealthcareSemiconductors
- Published
- 08 Sep 2026 12:53
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 48/100
- 30-day weight
- 5.4% of the score · 14.9d old
- Duplicates
- 1 consolidated
#1927Tone
Claim DepotDirect company coverageStored article
Claim your share of the $17 million Twist Bioscience securities class action settlement
Investors who purchased Twist Bioscience common stock between December 20, 2018, and November 15, 2022, or in its December 2020 secondary offering, may be eligible for a cash payment from a $17 million securities class action settlement. The lawsuit alleged that Twist Bioscience made false and misleading statements about its production process, product quality, and accounting, leading to inflated stock prices and investor losses. Eligible class members must submit a claim by November 17, 2026, with the estimated average net recovery being $0.22 per affected share.
FinanceLife Sciences
- Published
- 08 Sep 2026 10:44
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Dilution risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 57/100
- 30-day weight
- 15.3% of the score · 15.0d old
- Duplicates
- 1 consolidated
#20—Not directional
TrefisDirect company coverageScored from headline
Twist Bioscience Stock: 6 Straight Red Days, Down 19%
- Published
- 07 Sep 2026 06:57
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.2d old
- Duplicates
- 1 consolidated
#21—Not directional
Investing.com South AfricaDirect company coverageStored article
Cathie Wood’s ARK sees major stock moves with Robinhood and Twist Bioscience By Investing.com
Cathie Wood's ARK ETFs made several significant trades on Friday, September 4th, 2026, increasing its stake in Robinhood Markets, Veracyte, and Intellia Therapeutics. Conversely, ARK reduced its positions in Twist Bioscience Corporation and Tempus AI. These moves reflect ARK's continued focus on technology, healthcare, and innovation.
BlockchainFinancial MarketsLife SciencesTechnology
- Published
- 05 Sep 2026 00:58
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.4d old
- Duplicates
- 1 consolidated
#22—Not directional
careplusvn.comDirect company coverageScored from headline
Twist Bioscience (TWST) Slips 3.17% to $124.63 as Biotech Volatility Weighs on Sentiment - Volume Dry Up
- Published
- 04 Sep 2026 07:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.2d old
- Duplicates
- 1 consolidated
#2357Tone
simplywall.stDirect company coverageScored from headline
Twist Bioscience (TWST) After Margin Gains And Big Share Price Run Looks Fully Valued
- Published
- 01 Sep 2026 07:00
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 31/100
- 30-day weight
- 1% of the score · 22.2d old
- Duplicates
- 1 consolidated
#2425Tone
dars.gov.etDirect company coverageScored from headline
Twist (TWST) Results Check: EPS Comes in Below Forecast in the Latest Reading; Latest Reaction: The Market Price Moves 7.54% Higher in the Latest Session - Profit Margin Analysis
- Published
- 26 Aug 2026 07:00
- News subject
- Earnings
- Why this score
- Missed expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 51/100
- 30-day weight
- 0.8% of the score · 28.2d old
- Duplicates
- 1 consolidated
#2540Tone
GuruFocusDirect company coverageStored article
Twist Bioscience Corp (TWST) Stock Up 7.5% but GF Value Says Overvalued -- GF Score: 69/100
Twist Bioscience Corp (TWST) stock rose 7.5% today to $151.42, yet GuruFocus's GF Value™ indicates it is 188.0% overvalued compared to its fair value of $52.58. The company shows strong growth (10/10) but struggles with profitability (3/10) and is considered highly overvalued (1/10). Notably, insiders have sold $64.5M worth of shares over the past year with no buying activity, raising concerns about future prospects.
Financial MarketsLife Sciences
- Published
- 25 Aug 2026 23:47
- News subject
- Market update
- Why this score
- Negative valuation view, Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- <0.1% of the score · 28.5d old
- Duplicates
- 1 consolidated
#2640Tone
Stock TitanDirect company coverageStored article
Twist Bioscience (NASDAQ: TWST) COO sells shares in tax-withholding trade
Twist Bioscience Corp (TWST) President and COO Patrick John Finn sold 4,046 shares of common stock on August 21, 2026, for a total of $563,165. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations on vested Restricted Stock Units, not a discretionary trade. Following the sale, Finn directly holds 210,802 shares of TWST.
EarningsFinance
- Published
- 25 Aug 2026 19:41
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 0.6% of the score · 28.6d old
- Duplicates
- 1 consolidated
#2740Tone
Stock TitanDirect company coverageStored article
Twist Bioscience (NASDAQ: TWST) CFO sells shares to cover taxes
Twist Bioscience's CFO, Adam Laponis, sold 1,965 shares of common stock at $139.066 per share on August 21, 2026. This transaction was not a discretionary trade but rather a "sell to cover" action to satisfy tax withholding obligations related to the vesting of Restricted Stock Units. Following this sale, Laponis directly holds 108,633 shares of the company's common stock.
EarningsFinanceLife SciencesTechnology
- Published
- 25 Aug 2026 19:41
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 0.7% of the score · 28.6d old
- Duplicates
- 1 consolidated
#2840Tone
Stock TitanDirect company coverageStored article
Twist Bioscience (TWST) CEO trims stake in tax-driven sale
Twist Bioscience CEO Emily M. Leproust sold 6,639 shares of common stock on August 21, 2026, for $139.066 per share. This sale was a mandatory "sell to cover" transaction to fulfill tax withholding obligations on vested Restricted Stock Units, not a discretionary trade. Following the sale, Leproust directly holds 812,299 common shares, in addition to various employee stock options.
EarningsEconomy FiscalFinanceLife Sciences
- Published
- 25 Aug 2026 19:41
- News subject
- Earnings
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 0.7% of the score · 28.6d old
- Duplicates
- 1 consolidated
#29—Not directional
Stock TitanDirect company coverageStored article
Twist Bioscience (NASDAQ: TWST) officer sets 854-share sale tied to equity taxes
Robert F. Werner, an officer at Twist Bioscience Corp (TWST), has filed a Rule 144 notice to sell 854 shares of common stock. This proposed sale is connected to restricted stock vesting, with a portion of the proceeds intended to cover tax obligations from a vested equity award. The filing also notes several previous stock sales by Werner over the last three months.
FinanceFinancial MarketsLife Sciences
- Published
- 24 Aug 2026 19:42
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.6d old
- Duplicates
- 1 consolidated
#30—Not directional
Investing.comDirect company coverageStored article
Guggenheim reiterates Twist Bioscience stock rating on AI drug discovery potential
Guggenheim has reiterated a Buy rating and a $107.00 price target for Twist Bioscience (NASDAQ:TWST), citing the company's significant opportunities in AI-enabled drug discovery. Despite the stock's 409% surge over the past year and current trading near its 52-week high, InvestingPro data suggests it may be overvalued. Twist Bioscience expects triple-digit order growth in this sector for the current and next year, although short-seller Scorpion Capital has raised concerns regarding the company's role in an AI partnership with Anthropic.
EarningsLife SciencesTechnology
- Published
- 24 Aug 2026 11:42
- News subject
- Analyst action
- Why this score
- Buy Rating, Positive market reaction, Negative valuation view
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 30.0d old
- Duplicates
- 1 consolidated
Earlier company news
TWST news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Sep
18
2026
TrefisArchivedNeutral tone
Twist Bioscience Stock: 6 Straight Green Days, Up 24%
- Published
- 18 Sep 2026 09:58
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
24
2026
vinanet.vnArchivedNeutral tone
Twist (TWST) Q2 2026 Results: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.79% Up on the Day - Revenue Inflection Point
- Published
- 24 Aug 2026 08:43
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
24
2026
vinanet.vnArchivedNeutral tone
Twist (TWST) Q2 2026 Results: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.79% Up on the Day - Interim Report
- Published
- 24 Aug 2026 08:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
24
2026
careplusvn.comArchivedNeutral tone
Twist (TWST) Q2 2026 Results: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.79% Up on the Day - Revenue Report
- Published
- 24 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
21
2026
Stock TitanArchivedNeutral tone
Twist Bioscience (NASDAQ: TWST) seller plans more after $14.2M August stock trade
Emily M. Leproust, an insider at Twist Bioscience (TWST), has filed a Form 144 notice to sell 6,639 shares of common stock valued at $923,261.83. This planned sale is related to restricted stock vesting and includes funds to cover tax obligations from an equity award distribution. The filing also reveals previous sales by Leproust, including 113,318 shares worth over $14 million on August 10, 2026.
EarningsFinancial MarketsLife Sciences
- Published
- 21 Aug 2026 21:12
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
21
2026
StocksToTradeArchivedPositive tone
Twist Bioscience Stock Surges As Anthropic AI Deal And Upbeat Guidance Reset Outlook
Twist Bioscience (NASDAQ: TWST) stock surged by 6.79% following its Q3 earnings, an upsized equity offering, and a key AI-driven protein design project deal with Anthropic. The company beat revenue estimates, raised full-year fiscal 2026 guidance, and targets adjusted EBITDA breakeven in Q4. Despite an extreme valuation, the aggressive uptrend and institutional demand suggest continued bullish sentiment, with analysts converging on a re-rated fundamental value.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 21 Aug 2026 21:12
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
21
2026
Stock TitanArchivedNeutral tone
Twist Bioscience (NASDAQ: TWST) officer booked $1.84M in one sale, now plans more stock trades
An officer at Twist Bioscience (NASDAQ: TWST), Dennis H. Cho, plans to sell 1,598 shares of common stock worth approximately $222,228.11, primarily to cover tax obligations from a vested equity award. This follows multiple significant sales by Cho in the past three months, including a recent sale of 14,205 shares for $1,843,098.75 on August 19, 2026. The planned sale is documented in a Rule 144 notice filed with the SEC.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 21 Aug 2026 20:12
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
Seeking AlphaArchivedPositive tone
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now) (NASDAQ:TWST)
- Published
- 20 Aug 2026 21:36
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
Stock TitanArchivedNegative tone
Twist Bioscience (TWST) COO sells 78K shares under 10b5-1 plan
Twist Bioscience Corp (TWST) President and COO Patrick John Finn exercised stock options for 23,355 shares and subsequently sold a total of 78,355 shares of common stock. These transactions occurred on August 18, 2026, and were executed under a pre-adopted Rule 10b5-1 trading plan from May 18, 2026. The sales were made at weighted average prices ranging from approximately $115.35 to $122.815 per share.
FinanceFinancial MarketsLife Sciences
- Published
- 20 Aug 2026 20:42
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
MarketBeatArchivedNeutral tone
Twist Bioscience (NASDAQ:TWST) Shares Gap Down - Here's What Happened
Twist Bioscience (NASDAQ:TWST) shares gapped down before trading on Thursday, opening at $136.84 after closing at $142.39. Despite missing earnings expectations with a loss of $0.56 per share, the company exceeded revenue forecasts at $118.38 million. Analysts maintain a "Moderate Buy" consensus, though their average price target of $98.30 is significantly lower than the stock's current trading level.
EarningsFinancial MarketsLife Sciences
- Published
- 20 Aug 2026 18:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
Investing.comArchivedNeutral tone
Twist Bioscience stock hits 52-week high at 143.1 USD
Twist Bioscience (TWST) stock reached a new 52-week high of $143.10, currently trading at $143.35, reflecting a remarkable 438% return over the past year and a 349% gain year-to-date. Despite this surge and strong investor confidence, InvestingPro analysis suggests the stock may be overvalued. The company recently reported fiscal third-quarter 2026 revenue of $118.4 million, exceeding estimates, and continues its growth strategy despite skepticism from a short seller regarding its partnership with Anthropic.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 20 Aug 2026 18:10
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
SahmArchivedNeutral tone
Twist Bioscience Stock Hits 52-Week High - Here's Why
Twist Bioscience (NASDAQ: TWST) stock reached a new 52-week high after Anthropic selected the company as an independent evaluator for its AI models in protein design. Twist Bioscience is tasked with rapidly producing and testing AI-designed proteins to assess their binding capabilities, a crucial step in drug development. The company's stock shows strong technical indicators, including trading significantly above its moving averages and a recent golden cross formation.
Financial MarketsLife SciencesTechnology
- Published
- 20 Aug 2026 12:10
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
simplywall.stArchivedPositive tone
Why Did Twist Bioscience (TWST) Shares Jump Today?
- Published
- 20 Aug 2026 10:42
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
TipRanksArchivedPositive tone
Twist Bioscience tapped to validate Anthropic AI proteins
Twist Bioscience has been selected by Anthropic to mass-produce and validate AI-designed proteins from a 15-target campaign. This collaboration highlights Twist Bioscience's crucial role in bridging AI-generated protein concepts with laboratory validation, reinforcing its position in the AI-enabled biotechnology ecosystem. Despite current losses, Twist Bioscience (TWST) shows strong technical performance and raised revenue guidance, indicating a path to adjusted EBITDA breakeven.
EarningsFinanceLife SciencesTechnology
- Published
- 20 Aug 2026 10:42
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
Seeking AlphaArchivedPositive tone
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now) (NASDAQ:TWST)
- Published
- 20 Aug 2026 08:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
dars.gov.etArchivedNegative tone
Twist (TWST) Results at a Glance: EPS Misses Its Estimate in the Available Record; Investor Response: The Stock Gains 22.64% in the Latest Reading - EPS Estimate Trend
- Published
- 20 Aug 2026 03:44
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
vinanet.vnArchivedNegative tone
Twist (TWST) Results at a Glance: EPS Misses Its Estimate in the Available Record; Investor Response: The Stock Gains 22.64% in the Latest Reading - Post-Earnings Reaction
- Published
- 20 Aug 2026 03:34
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
vinanet.vnArchivedNegative tone
Twist (TWST) Results at a Glance: EPS Misses Its Estimate in the Available Record; Investor Response: The Stock Gains 22.64% in the Latest Reading - Net Profit Margin
- Published
- 20 Aug 2026 03:33
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
20
2026
vinanet.vnArchivedPositive tone
Twist (TWST) Outlook: Posts a 22.64% Gain to $142.39 for the Current Session; Levels: $135.27 and $149.51 Define the Nearby Reference Levels in the Available Record - NHNL Ratio
- Published
- 20 Aug 2026 00:48
- Catalyst
- Guidance
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
TipRanksArchivedNeutral tone
Twist Bioscience Registers Invenra Share Resale Prospectus
Twist Bioscience (TWST) has filed a prospectus supplement to register the resale of shares issued to Invenra Inc. under a Stock Purchase Agreement from February 2026, supported by a legal opinion from Orrick, Herrington & Sutcliffe LLP. The company's stock currently holds a "Buy" rating from analysts with a $115 price target, though TipRanks' AI Analyst "Spark" rates TWST as "Neutral" due to weak financial performance despite strong technicals and recent positive corporate updates.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 19 Aug 2026 23:40
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
Stock TitanArchivedNeutral tone
Twist Bioscience (NASDAQ: TWST) clears path for 35K-share resale
Twist Bioscience (NASDAQ: TWST) has filed a prospectus supplement to register for resale up to 35,114 shares of common stock held by Invenra Inc. These shares were issued under a Stock Purchase Agreement and may be sold over time through various brokerage or privately negotiated transactions. Twist Bioscience will not receive any proceeds from these sales, only covering registration-related expenses, and the filing also renews registration after a previous automatic shelf filing expired.
Financial MarketsLife Sciences
- Published
- 19 Aug 2026 22:40
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
StocksToTradeArchivedPositive tone
Twist Bioscience Stock Rallies As Guidance And Targets Jump
Twist Bioscience (TWST) stock surged over 22% following strong Q3 revenue, increased guidance for Q4 and FY26, and bullish analyst upgrades. The company's management projects adjusted EBITDA breakeven for Q4, signaling a clearer path to profitability, and an upsized equity offering provides capital for growth despite dilution. Analysts from TD Cowen, Piper Sandler, and Baird all raised their price targets to $115, citing demand driven by AI-enabled drug discovery.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 19 Aug 2026 21:47
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
timothysykes.comArchivedPositive tone
Twist Bioscience Stock Jumps As Analysts Hike Targets
- Published
- 19 Aug 2026 21:47
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
StocksToTradeArchivedPositive tone
Twist Bioscience Stock Rallies On Guidance Hike And $300M Raise
Twist Bioscience stock rallied by 19.58% following strong Q3 earnings, an upbeat FY26 revenue outlook of $456M–$457M, and a target for adjusted EBITDA breakeven in Q4. The company also announced an upsized $300M equity offering at $96 per share to fund R&D and expansion, which analysts like TD Cowen, Piper Sandler, and Baird view positively, raising their price targets to $115 due to the company's growth and AI-enabled drug discovery narrative. While dilution risks exist from the offering, the capital infusion is expected to support future profitable growth.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 19 Aug 2026 20:03
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
MT NewswiresArchivedNeutral tone
Twist Bioscience Shares Rise After Selection by Anthropic to Evaluate Protein Design Project
- Published
- 19 Aug 2026 19:46
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
StocksToTradeArchivedPositive tone
Twist Bioscience Stock Rallies As Guidance And Targets Jump
Twist Bioscience (TWST) stock surged over 22% following strong Q3 revenue, increased guidance for Q4 and FY26, and bullish analyst upgrades. The company's management projects adjusted EBITDA breakeven for Q4, signaling a clearer path to profitability, and an upsized equity offering provides capital for growth despite dilution. Analysts from TD Cowen, Piper Sandler, and Baird all raised their price targets to $115, citing demand driven by AI-enabled drug discovery.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 19 Aug 2026 17:47
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
StocksToTradeArchivedNeutral tone
Twist Bioscience (TWST) Stock Draws Bulls After Guidance Hike And $300M Raise
Twist Bioscience (TWST) stock surged over 17% after raising its fiscal 2026 revenue guidance to $456M–$457M and projecting adjusted EBITDA breakeven for Q4, exceeding analyst expectations. The company also completed a $300M secondary offering to fund R&D and manufacturing expansion, further bolstering confidence despite a wider Q3 loss. Analysts from TD Cowen, Piper Sandler, and Baird all increased their price targets to $115, citing strong demand for AI-enabled drug discovery and a clear path to a cash-generative model.
EarningsFinancial MarketsLife Sciences
- Published
- 19 Aug 2026 17:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 3 consolidated
Aug
19
2026
GuruFocusArchivedNegative tone
TWST Looks 163.5% Overvalued on GF Value™
Twist Bioscience (NASDAQ: TWST) saw its shares surge over 15% after Anthropic selected it as an independent evaluator for AI-generated protein binders, highlighting growing interest in AI-leveraging biotech. Despite its innovative DNA synthesis platform, the company's GF Value™ suggests it is 163.5% overvalued, and it remains unprofitable with a high price-to-sales ratio. While institutional interest is mixed, insider selling indicates a cautious sentiment from management, advising investors to consider both growth prospects and significant valuation concerns.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 19 Aug 2026 17:06
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
MarketBeatArchivedNeutral tone
Twist Bioscience (NASDAQ:TWST) Hits New 52-Week High - Should You Buy?
Twist Bioscience (NASDAQ:TWST) recently hit a new 52-week high, trading as high as $140.95. Despite positive analyst sentiment with a "Moderate Buy" consensus, the average price target of $98.30 is significantly below the current share price. The company reported a 23.2% year-over-year revenue increase to $118.38 million, beating estimates, but missed on EPS and is expected to remain unprofitable for the full year.
EarningsFinanceFinancial MarketsLife SciencesTechnology
- Published
- 19 Aug 2026 15:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
19
2026
Investing.comArchivedPositive tone
Why is Twist Bioscience stock surging today?
Twist Bioscience Corp (TWST) stock surged over 15% after Anthropic's research revealed its Claude AI models successfully designed protein binders, with Twist chosen to produce and validate these AI-designed proteins. This collaboration, formally disclosed in an 8-K filing, highlights Twist's central role in AI-driven drug discovery. The news, coupled with existing growth projections for AI-enabled drug discovery, pushed shares to a new 52-week high.
EarningsFinancial MarketsLife SciencesTechnology
- Published
- 19 Aug 2026 15:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to TWST, but the headline and available text are not mainly about Twist Bioscience Corp. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of TWST sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.